Company Profiles

driven by the PitchBook Platform

Presidio Pharmaceuticals

Description

Developer of small-molecule antiviral therapeutics designed to treat hepatitis C virus (HCV) infection. The company's antiviral therapeutics offer once-daily oral dosing and can be combined with other classes of HCV antivirals to combat viral resistance, enabling patients to access effective drug therapies against a variety of known HCV genotypes.

2006

Founded

PRIVATE

Status

11-50

Employees

Series D

Latest Deal Type

$21.8M

Latest Deal Amount

$90.7M

Total Amount Raised

Description

Developer of small-molecule antiviral therapeutics designed to treat hepatitis C virus (HCV) infection. The company's antiviral therapeutics offer once-daily oral dosing and can be combined with other classes of HCV antivirals to combat viral resistance, enabling patients to access effective drug therapies against a variety of known HCV genotypes.

Website:

www.presidiopharma.com

Ownership Status

Privately held (backing)

Financing Status

Venture Capital-Backed

Primary Industry

Pharmaceuticals

Other Industries

Other Pharmaceuticals and Biotechnology
Drug Discovery

Primary Office

1700 Owens Street Suite 585 San Francisco, CA 94158United States +1 (415) 655-7560
Request a free trial to the PitchBook Platform
You're viewing a free company profile from the PitchBook Platform. To explore Presidio Pharmaceuticals's full profile, request a free trial.

Presidio Pharmaceuticals Valuation and Funding

Request access
Deal TypeDateAmountRaised to DatePost-ValStatusStage

Presidio Pharmaceuticals Cap Table

Stock# of Shares
Authorized
Par ValueDividend Rate (%)Original
Issue Price
LiquidationLiquidation
Pref. Multiple
Conversion
Price
% Owned

Presidio Pharmaceuticals Investors (10)

Request access
Investor NameInvestor TypeHoldingInvestor SinceParticipating RoundsBoard
Seat
Contact
Info
Baker Brothers InvestmentsPE/BuyoutMinority000 0000000 0000
Bay City CapitalVenture CapitalMinority000 0000000 0000
Crown Predator HoldingsVenture CapitalMinority000 0000000 0000
Five Corners CapitalVenture CapitalMinority000 0000000 0000
MedivirCorporationMinority000 0000000 0000
Baker Brothers Investments PE/Buyout
Bay City Capital Venture Capital
Crown Predator Holdings Venture Capital
Five Corners Capital Venture Capital
Medivir Corporation

Presidio Pharmaceuticals Executive Team (5)

NameTitleBoard
Seat
Contact
Info
Leo RedmondChief Financial Officer, Secretary, Board Member & Acting President
Richard Colonno Ph.DChief Scientific Adviser
Leping Li Ph.DChemistry Adviser
Eric RubyRegulatory Affairs Adviser
Omar Haffar Ph.DCo-Founder & Board Member
Leo Redmond Chief Financial Officer, Secretary, Board Member & Acting President
Richard Colonno Ph.D Chief Scientific Adviser
Leping Li Ph.D Chemistry Adviser
Eric Ruby Regulatory Affairs Adviser
Omar Haffar Ph.D Co-Founder & Board Member

Presidio Pharmaceuticals Board Members (9)

NameRepresentingRoleSinceContact
Info
Dayton MisfeldtBay City CapitalManaging Director & Partner000 0000
Farid GhazzaouiPresidio PharmaceuticalsBoard Member000 0000
Felix Baker Ph.DBaker Brothers InvestmentsCo-Founder & Managing Partner000 0000
H. Daniel Perez MDBay City CapitalAdvisor000 0000
Jack Obijeski Ph.DSelfBoard Member000 0000
Dayton Misfeldt Managing Director & Partner Bay City Capital
Farid Ghazzaoui Board Member Presidio Pharmaceuticals
Felix Baker Ph.D Co-Founder & Managing Partner Baker Brothers Investments
H. Daniel Perez MD Advisor Bay City Capital
Jack Obijeski Ph.D Board Member Self
Request full access to PitchBook